Access to new medicines in Greece remains severely limited, with only one in five new treatments making it to patients. This situation reflects ongoing challenges in the healthcare system.
Patients are reportedly waiting almost two years to receive access to these new therapies, which raises concerns about the timeliness of medical advancements in the country.
Additionally, pharmaceutical companies are increasingly indicating that they do not plan to launch new products in Greece, further complicating the landscape for patients seeking innovative treatments.